Indication:
Olarigen capsules, containing 50 mg of Olaparib, are prescribed for treating specific cancers like ovarian, breast, and prostate cancer.

Pharmacology:
Olaparib, the active ingredient in Olarigen capsules, is a poly (ADP-ribose) polymerase (PARP) inhibitor. It hinders the PARP enzyme responsible for repairing damaged DNA in cancer cells, preventing their repair and leading to cell death.

Dosage and Administration:**
The recommended dose of Olarigen capsules is typically taken orally, with or without food, as directed by a healthcare professional. Dosage adjustments may occur based on individual patient factors and cancer type and stage.

Interaction:
Olarigen may interact with various drugs, including other chemotherapy agents and those metabolized by cytochrome P450 enzymes. Patients should inform their healthcare provider about all medications, supplements, and herbs they are taking to avoid potential interactions.

Side Effects:
Common side effects of Olarigen capsules include nausea, vomiting, fatigue, diarrhea, and reduced appetite. Severe effects like bone marrow suppression, increased infection risk, and lung issues may also arise. Patients should report severe or persistent side effects to their healthcare provider.

Precautions and Warnings:
Close monitoring for adverse reactions, particularly bone marrow suppression and lung problems, is necessary during Olarigen treatment. Pregnant women should avoid Olarigen due to potential fetal harm, and contraception is advised for both genders during and after treatment. Breastfeeding while taking Olarigen is not recommended.

Overdose Effects:
Olarigen overdose can intensify side effects such as bone marrow suppression and infection risk. Managing an overdose involves supportive care and monitoring for complications, with immediate medical attention necessary if overdose is suspected.